Asthma preventive drugs market led by GlaxoSmithKline's Advair
The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 4.5% through to 2015, driven by the increasing incidence of asthma along with the increased focus on contract manufacturing outsourcing, according to a new report added to the offering of Companiesandmarkets.com
Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers and with drug therapy.
Over 300 million people suffer from asthma. The global asthma drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 5.7% over the next five years, and to increase from a market value of $15.3 billion recorded in 2012, to hit $20.2 billion by 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze